In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford ...

Number 1: Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for ...

Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics ...

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face challenges like price erosion and potential shortages.

The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion ...

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, analyzes the need for innovative risk-sharing models to promote ...

The Inflation Reduction Act (IRA) has modestly boosted oncology biosimilar uptake through Medicare reimbursement, but its ...

The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory ...

An observational study assessing patient satisfaction with adalimumab for inflammatory bowel disease (IBD) reported a high ...

Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and ...